Adam B. Weiner, Urologic Oncologist at Cedars Sinai Medical Center, shared on X:
“Practice-changing in MIBC.
KEYNOTE-B15 shows perioperative enfortumab vedotin + pembrolizumab outperformed neoadjuvant cisplatin/gemcitabine in cisplatin-eligible patients:
- 2-year EFS: 79.4% vs 66.2% (HR 0.53)
- OS: HR 0.65
- pCR: 55.8% vs 32.5%
- More grade ≥3 AEs: 75.7% vs 67.2%
After >20 years, a non-platinum perioperative regimen beats cisplatin-based chemotherapy in resectable MIBC.
Alongside NIAGARA, perioperative therapy is redefining the standard of care.”
Title: Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
Authors: Matthew D. Galsky, Begoña P. Valderrama, Marco Maruzzo, Albert Font, Tudor Ciuleanu, Jonathan Chatzkel, Takuya Koie
Other articles about Bladder Cancer on OncoDaily.
